tiprankstipranks
Advertisement
Advertisement

Conmed Secures New Credit Agreement with JPMorgan

Story Highlights
  • CONMED entered a new credit agreement on June 10, 2025, with extended maturity to 2030.
  • The agreement includes a $550 million revolving credit facility and changes to financial covenants.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Conmed Secures New Credit Agreement with JPMorgan

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Conmed ( (CNMD) ) has provided an update.

On June 10, 2025, CONMED Corporation and its subsidiary Linvatec Nederland B.V. entered into an Eighth Amended and Restated Credit Agreement with several financial institutions, including JPMorgan Chase Bank, N.A. This agreement, which amends a previous credit agreement from July 16, 2021, provides CONMED with a $550 million U.S. dollar revolving credit facility, a $100 million multicurrency revolving credit facility, and a $100 million term loan facility. The new agreement extends the maturity of these facilities to June 10, 2030, and introduces changes such as a minimum interest coverage ratio and the removal of mandatory prepayments for excess cash flow. The credit agreement is secured by CONMED’s assets and includes customary covenants and events of default, potentially impacting the company’s financial operations and strategic flexibility.

The most recent analyst rating on (CNMD) stock is a Buy with a $106.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.

Spark’s Take on CNMD Stock

According to Spark, TipRanks’ AI Analyst, CNMD is a Outperform.

Conmed’s overall stock score reflects solid financial performance and positive earnings call insights, with strong revenue growth and improved guidance being the most significant factors. Technical indicators suggest neutral momentum, and valuation appears reasonable. While supply chain and international sales challenges remain, the company’s operational improvements and strategic focus provide a positive outlook.

To see Spark’s full report on CNMD stock, click here.

More about Conmed

CONMED Corporation is a company involved in the medical technology industry, providing surgical devices and equipment. It focuses on delivering innovative solutions for minimally invasive procedures across various medical specialties.

Average Trading Volume: 449,606

Technical Sentiment Signal: Sell

Current Market Cap: $1.66B

Find detailed analytics on CNMD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1